INDEPENDENT NEWS

CLC Bio Part of $ 10M EU PATHSEEK Project

Published: Fri 31 Aug 2012 10:47 AM
FOR IMMEDIATE RELEASE
CLC Bio Part of $ 10M EU PATHSEEK Project
Aarhus, Denmark -- August 30, 2012 -- CLC bio, the world's leading bioinformatics software developer, has been awarded a share of a EU-funded clinical research grant, PATHSEEK, worth $ 2 million out of a total project budget of $ 10 million.
As part of the grant, CLC bio will develop a user-friendly and computationally efficient solution for pathogen identification, host biomarker identification, pathogen variant characterization and molecular epidemiology in a clinical setting, as well as build a flexible computational back-end.
VP of R at CLC bio, Dr. Roald Forsberg, comments, "Current platforms in diagnostic laboratories are limited by the amount of time required for generating a result and by the limited sequence information available for pathogens. To overcome these limitations we’re going to develop a disruptive diagnostic technological pathogen sequencing platform which utilizes our world-leading bioinformatics expertise to enable scientists to go from a patient sample to a result, in less than 48 hours."
CEO of CLC bio, Thomas Knudsen, adds, "From the start, it has been one of CLC bio’s core strategies to do active research within the bioinformatics field and letting that research be a primary driver of our software development. We're currently part of and coordinating 10 different research projects, of which half are funded by the EU. This underlines our successful strategy and we plan to be part of even more research grants in the future."
About PATHSEEK
PATHSEEK is a 3-year study led by Professor Judy Breuer at University College London, which will demonstrate the potential of next generation sequencing technologies in clinical microbiology labs, to enable the detection of pathogens directly from clinical samples and the early detection of drug resistant mutations. The study will look at infections with clear unmet clinical needs or which pose a global risk, including, HIV, Mycobacterium tuberculosis, hepatitis B (HBV) and C (HCV) and influenza A. PATHSEEK will also investigate two host pharmacogenomics biomarkers which predict response to therapy for HCV and HIV.
The partners in PATHSEEK include University College London (UK), Erasmus Universitair Medisch Centrum Rotterdam (NL), Oxford Gene Technology (UK), and CLC bio (DK).
About CLC bio
http://www.clcbio.com/about
ENDS

Next in Business, Science, and Tech

Buy-now, Pay-later Raking In $10m+ In Late Fees Annually
By: Consumer NZ
Catherine Mcgrath Appointed CEO, Westpac New Zealand
By: Westpac New Zealand
AWS To Open Data Centres In New Zealand
By: Amazon Web Services
Surge In Imports Results In Record Monthly Trade Deficit
By: Statistics New Zealand
Fonterra completes reset, announces annual results and long-
By: Fonterra
GDP rises in the June 2021 quarter
By: Statistics New Zealand
National Welcomes Amazon’s Investment In New Zealand’s Digital Future
By: New Zealand National Party
View as: DESKTOP | MOBILE © Scoop Media